A study led by USC Norris Comprehensive Cancer Center, part of the Keck School of Medicine of USC, analyzed data on red and processed meat intake from 29,842 people with colorectal cancer and 39,635 people without cancer.
In a paper published in The Lancet Public Health, researchers sound a clarion call for greater investment, at both the community and institutional level, in establishing support for grief-related suffering.
A phase I CAR T-cell therapy trial for the treatment of glioblastoma demonstrated promising clinical activity, according to research published in Nature Medicine.
Insights into the workings of PD-1 reveal how treatments that restrict its action can potentially be strengthened to improve their anticancer effect, a new study shows.
Cancer Center at Illinois member Jeff Chan, associate professor of chemistry, recently published research demonstrating the development of an activatable cancer therapeutic to help eliminate the side effects of traditional chemotherapies.
In a pilot study, a telephone-based dietary intervention designed to improve bowel function was shown to be widely acceptable to participants who had had surgery for rectal cancer.
In a policy statement, the American Society of Clinical Oncology calls for global equity in clinical trials.
The International Agency for Research on Cancer published a report titled “Maternal Orphans due to Cancer: The intergenerational impact of cancer deaths in women,” summarizing the findings from previous publications by researchers from IARC and partners that dealt with the theme of the intergenerational impact of cancer deaths in women.
An interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or refractory multiple myeloma, showed that the trial met its primary endpoint of progression-free survival at a prespecified interim analysis and was unblinded early based on the recommendation by an Independent Data Monitoring Committee.
Researchers from the UCLA Health Jonsson Comprehensive Cancer Center showed for the first time that a gene usually linked to giant axonal neuropathy, a rare and severe neurological condition, also plays a role in inhibiting aggressive tumor cell growth in head and neck cancers.
